BioCardia, Inc.
BCDADrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Autologous cell therapy | Phase 3 | Heart Failure, Systolic | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BioCardia, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in BioCardia, Inc.'s (BCDA) pipeline across Phase 3. Its lead program is Autologous cell therapy (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioCardia, Inc.'s next FDA catalyst?→
BioCardia, Inc.'s (BCDA) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BCDA biotech catalysts?→
Add BCDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioCardia, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.